Cardinal Capital Management lifted its holdings in Haemonetics Co. (NYSE:HAE) by 2.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,260 shares of the medical instruments supplier’s stock after buying an additional 160 shares during the period. Cardinal Capital Management’s holdings in Haemonetics were worth $722,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in Haemonetics by 1.6% in the fourth quarter. BlackRock Inc. now owns 6,026,806 shares of the medical instruments supplier’s stock valued at $602,982,000 after buying an additional 92,894 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Haemonetics by 1.9% in the third quarter. Vanguard Group Inc. now owns 5,619,707 shares of the medical instruments supplier’s stock worth $643,906,000 after purchasing an additional 107,357 shares during the period. Vanguard Group Inc increased its stake in Haemonetics by 1.9% in the third quarter. Vanguard Group Inc now owns 5,619,707 shares of the medical instruments supplier’s stock valued at $643,906,000 after acquiring an additional 107,357 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Haemonetics by 8.8% in the third quarter. Bank of New York Mellon Corp now owns 854,775 shares of the medical instruments supplier’s stock valued at $97,942,000 after acquiring an additional 69,094 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in Haemonetics by 7.7% in the third quarter. Deutsche Bank AG now owns 803,718 shares of the medical instruments supplier’s stock valued at $92,086,000 after acquiring an additional 57,782 shares during the last quarter. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Haemonetics stock traded down $0.17 during mid-day trading on Thursday, reaching $88.63. 213,439 shares of the company traded hands, compared to its average volume of 442,649. The firm has a market capitalization of $4.50 billion, a price-to-earnings ratio of 47.41, a PEG ratio of 2.31 and a beta of 0.88. Haemonetics Co. has a fifty-two week low of $72.85 and a fifty-two week high of $117.56. The company has a current ratio of 2.44, a quick ratio of 1.64 and a debt-to-equity ratio of 0.51.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $0.63 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.04. Haemonetics had a net margin of 4.84% and a return on equity of 17.05%. The firm had revenue of $247.36 million for the quarter, compared to the consensus estimate of $250.12 million. During the same period in the prior year, the firm posted $0.62 earnings per share. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. On average, sell-side analysts predict that Haemonetics Co. will post 2.33 EPS for the current fiscal year.

A number of analysts have recently weighed in on HAE shares. Zacks Investment Research lowered shares of Haemonetics from a “buy” rating to a “sell” rating in a report on Tuesday, January 8th. ValuEngine cut shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 5th. Finally, Barrington Research lifted their target price on shares of Haemonetics to $112.00 and gave the company a “positive” rating in a research note on Wednesday, February 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $119.75.

In other news, EVP Michelle L. Basil sold 391 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $83.57, for a total transaction of $32,675.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Dan Goldstein sold 3,206 shares of the company’s stock in a transaction dated Tuesday, April 9th. The shares were sold at an average price of $88.90, for a total transaction of $285,013.40. The disclosure for this sale can be found here. Insiders have sold a total of 11,909 shares of company stock valued at $1,036,501 in the last 90 days. Insiders own 1.04% of the company’s stock.

WARNING: “Haemonetics Co. (HAE) Holdings Boosted by Cardinal Capital Management” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/haemonetics-co-hae-holdings-boosted-by-cardinal-capital-management/2955795.html.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Read More: Quiet Period Expirations Explained

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.